Single- and Multiple-dose Pharmacokinetics of a Lorcaserin Extended-release Tablet

详细信息    查看全文

• 作者：Ronald Christopher ; PhD¹ ; ^{rchristopher@arenapharm.com" class="auth_mail" title="E-mail the corresponding author} ; Mike Morgan ; PhD¹ ; Jim Ferry ; PhD² ; Bhaskar Rege ; PhD² ; Yong Tang ; PhD¹ ; Allan Kristensen ; MS² ; William Shanahan ; MD¹
• 关键词：extended-release ; lorcaserin ; obesity ; overweight ; pharmacokinetic properties
• 刊名：Clinical Therapeutics
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：38
• 期：10
• 页码：2227-2238.e4
• 全文大小：470 K

文摘

Lorcaserin is a serotonin 2C receptor agonist indicated for chronic weight management as an adjunct to diet and exercise. The initial approved formulation is a 10-mg, immediate-release (IR) tablet for administration BID. These studies investigated the single- and multiple-dose pharmacokinetic properties of a new, recently US Food and Drug Administration–approved, extended-release, 20-mg once-daily formulation.

Methods

We performed 2 separate 2-period, 2-sequence crossover studies in 36 healthy adults: a study comparing the IR formulation to the extended-release formulation under fasting conditions and a study comparing the extended-release formulation under fed and fasted conditions.

Findings

Compared with lorcaserin IR, the T_max after a single dose of lorcaserin extended-release was greater (median, 12 vs 3 hours), and the C_max was 26% lower (38.8 vs 52.3 ng/mL). AUC data were bioequivalent for the 2 formulations in both single- and multiple-dose regimens, confirming no formulation effect on lorcaserin bioavailability. In fasted and fed conditions, T_max after a single dose was identical (median, 12 hours), but C_max was approximately 45% higher in the fed state (mean, 38.5 ng/mL fasted vs 56.1 ng/mL fed). However, at steady state, C_max and AUC were determined to be bioequivalent between the fasted and fed states, indicating no clinically relevant food effect on the pharmacokinetic properties of lorcaserin extended-release. The safety profile was consistent between the 2 formulations.

Implications

Overall, the results indicate that lorcaserin extended-release is a suitable once-daily alternative to the approved IR BID formulation.